Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

8.320 -0.190 (-2.23%)
Streaming Delayed Price Updated: 12:34 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
INVESTOR ALERT: NeoGenomics, Inc. Investors with Substantial Losses Have Opportunity to Lead the NeoGenomics Class Action Lawsuit - NEO
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
CORRECTING and REPLACING NEOGENOMICS INVESTOR ALERT: Gibbs Law Group Files Class Action Lawsuit on Behalf of NEO Investors
From Gibbs Law Group
Via Business Wire
NeoGenomics Announces Chief Financial Officer Transition
Via ACCESSWIRE
NeoGenomics Reports Third Quarter 2022 Results
Via ACCESSWIRE
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
Via ACCESSWIRE
SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Class Action on Behalf of Investors in NeoGenomics, Inc. and Advises Shareholders with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END 
Via FinancialNewsMedia
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
Via ACCESSWIRE
NeoGenomics Announces Chief Executive Officer Appointment
Via ACCESSWIRE
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
Via ACCESSWIRE
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
Via ACCESSWIRE
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors
Via ACCESSWIRE
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
Via ACCESSWIRE
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
Via ACCESSWIRE
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
NeoGenomics Announces Chief Executive Officer Appointment
Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms... 
From NeoGenomics, Inc.
Via AccessWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D 
From NeoGenomics, Inc.
Via AccessWire
NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc.
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Certain directors of NeoGenomics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics Appoints Lynn Tetrault Interim CEO
FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,... 
From NeoGenomics, Inc.
Via AccessWire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.